BioCentury

7:00 AM GMT, Aug 1, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Clinical Results

DR Cysteamine cysteamine bitartrate: Phase III data

Additionally, the mean total daily, steady-state dose of DR Cysteamine was 82% of patient's incoming dose of Cystagon. There was

Read the full 203 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.